TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Nov. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 1, 2023, TransMedics...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Grants | Heart | Heart Transplant | Liver | Liver Transplant | Lung Transplant | Pharmaceuticals | Transplant Surgery | Transplants | Urology & Nephrology